Kodiak Sciences (NYSE:KOD) Trading Up 1.8%

Kodiak Sciences Inc. (NYSE:KOD)’s stock price was up 1.8% during trading on Wednesday . The stock traded as high as $14.37 and last traded at $13.81, approximately 2,590 shares changed hands during mid-day trading. A decline of 98% from the average daily volume of 111,974 shares. The stock had previously closed at $13.56.

KOD has been the topic of a number of recent research reports. Chardan Capital reaffirmed a “buy” rating and set a $22.50 price objective on shares of Kodiak Sciences in a research report on Thursday, June 13th. Zacks Investment Research lowered Kodiak Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, July 24th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $17.50.

The stock has a 50-day moving average price of $11.76 and a 200 day moving average price of $9.77.



Kodiak Sciences (NYSE:KOD) last issued its earnings results on Wednesday, August 14th. The company reported ($0.31) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.02).

Several large investors have recently made changes to their positions in KOD. Geode Capital Management LLC acquired a new stake in shares of Kodiak Sciences during the 4th quarter worth about $458,000. Deutsche Bank AG acquired a new stake in Kodiak Sciences during the fourth quarter worth approximately $87,000. SG Americas Securities LLC acquired a new stake in Kodiak Sciences during the first quarter worth approximately $66,000. Marshall Wace LLP purchased a new stake in shares of Kodiak Sciences during the 1st quarter worth approximately $258,000. Finally, Marshall Wace North America L.P. purchased a new stake in shares of Kodiak Sciences during the 1st quarter worth approximately $73,000.

About Kodiak Sciences (NYSE:KOD)

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, provides novel therapeutics to treat ophthalmic diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biologic that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy.

Further Reading: Understanding Stock Ratings

Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.